Literature DB >> 27273071

Reduced sCD36 following weight loss corresponds to improved insulin sensitivity, dyslipidemia and liver fat in obese children.

L Knøsgaard1, K Kazankov2, N H Birkebæk3, P Holland-Fischer3, A Lange3, J Solvig4, A Hørlyck4, K Kristensen3, S Rittig3, H Vilstrup2, H Grønbæk2, A Handberg1,5.   

Abstract

BACKGROUND/
OBJECTIVES: Childhood obesity is a major health problem with serious long-term metabolic consequences. CD36 is important for the development of obesity-related complications among adults. We aimed to investigate circulating sCD36 during weight loss in childhood obesity and its associations with insulin resistance, dyslipidemia, hepatic fat accumulation and low-grade inflammation. SUBJECTS/
METHODS: The impact of a 10-week weight loss camp for obese children (N=113) on plasma sCD36 and further after a 12-month follow-up (N=68) was investigated. Clinical and biochemical data were collected, and sCD36 was measured by an in-house assay. Liver fat was estimated by ultrasonography and insulin resistance by the homeostasis model assessment (HOMA-IR).
RESULTS: Along with marked weight loss, sCD36 was reduced by 21% (P=0.0013) following lifestyle intervention, and individual sCD36 reductions were significantly associated with the corresponding decreases in HOMA-IR, triglycerides and total cholesterol. The largest sCD36 decrease occurred among children who reduced HOMA-IR and liver fat. After 12 months of follow-up, sCD36 was increased (P=0.014) and the metabolic improvements were largely lost.
CONCLUSIONS: Weight-loss-induced sCD36 reduction, coincident with improved insulin resistance, circulating lipids and hepatic fat accumulation, proposes that sCD36 may be an early marker of long-term health risk associated with obesity-related complications.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 27273071     DOI: 10.1038/ejcn.2016.88

Source DB:  PubMed          Journal:  Eur J Clin Nutr        ISSN: 0954-3007            Impact factor:   4.016


  40 in total

1.  Hepatic fatty acid translocase CD36 upregulation is associated with insulin resistance, hyperinsulinaemia and increased steatosis in non-alcoholic steatohepatitis and chronic hepatitis C.

Authors:  María Eugenia Miquilena-Colina; Elena Lima-Cabello; Sonia Sánchez-Campos; María Victoria García-Mediavilla; Miguel Fernández-Bermejo; Tamara Lozano-Rodríguez; Javier Vargas-Castrillón; Xabier Buqué; Begoña Ochoa; Patricia Aspichueta; Javier González-Gallego; Carmelo García-Monzón
Journal:  Gut       Date:  2011-01-26       Impact factor: 23.059

Review 2.  CD36 genetics and the metabolic complications of obesity.

Authors:  Latisha Love-Gregory; Nada A Abumrad
Journal:  Curr Opin Clin Nutr Metab Care       Date:  2011-11       Impact factor: 4.294

3.  CD36 level and trafficking are determinants of lipolysis in adipocytes.

Authors:  Dequan Zhou; Dmitri Samovski; Adewole L Okunade; Philip D Stahl; Nada A Abumrad; Xiong Su
Journal:  FASEB J       Date:  2012-07-19       Impact factor: 5.191

4.  Effect of a 10-week weight loss camp on fatty liver disease and insulin sensitivity in obese Danish children.

Authors:  Henning Grønbæk; Aksel Lange; Niels H Birkebæk; Peter Holland-Fischer; Jan Solvig; Arne Hørlyck; Kurt Kristensen; Søren Rittig; Hendrik Vilstrup
Journal:  J Pediatr Gastroenterol Nutr       Date:  2012-02       Impact factor: 2.839

5.  Serum soluble CD36, assessed by a novel monoclonal antibody-based sandwich ELISA, predicts cardiovascular mortality in dialysis patients.

Authors:  Michal Chmielewski; Ann-Christin Bragfors-Helin; Peter Stenvinkel; Bengt Lindholm; Björn Anderstam
Journal:  Clin Chim Acta       Date:  2010-09-16       Impact factor: 3.786

6.  CD36 in myocytes channels fatty acids to a lipase-accessible triglyceride pool that is related to cell lipid and insulin responsiveness.

Authors:  Claire C Bastie; Tahar Hajri; Victor A Drover; Paul A Grimaldi; Nada A Abumrad
Journal:  Diabetes       Date:  2004-09       Impact factor: 9.461

7.  Soluble CD36 and risk markers of insulin resistance and atherosclerosis are elevated in polycystic ovary syndrome and significantly reduced during pioglitazone treatment.

Authors:  Dorte Glintborg; Kurt Højlund; Marianne Andersen; Jan Erik Henriksen; Henning Beck-Nielsen; Aase Handberg
Journal:  Diabetes Care       Date:  2007-11-13       Impact factor: 19.112

8.  Adipose expression of tumor necrosis factor-alpha: direct role in obesity-linked insulin resistance.

Authors:  G S Hotamisligil; N S Shargill; B M Spiegelman
Journal:  Science       Date:  1993-01-01       Impact factor: 47.728

9.  The impact of exercise training compared to caloric restriction on hepatic and peripheral insulin resistance in obesity.

Authors:  Robert H Coker; Rick H Williams; Sophie E Yeo; Patrick M Kortebein; Don L Bodenner; Philip A Kern; William J Evans
Journal:  J Clin Endocrinol Metab       Date:  2009-10-06       Impact factor: 5.958

10.  Soluble CD36 in plasma is increased in patients with symptomatic atherosclerotic carotid plaques and is related to plaque instability.

Authors:  Aase Handberg; Mona Skjelland; Annika E Michelsen; Ellen Lund Sagen; Kirsten Krohg-Sørensen; David Russell; Arve Dahl; Thor Ueland; Erik Oie; Pål Aukrust; Bente Halvorsen
Journal:  Stroke       Date:  2008-08-21       Impact factor: 7.914

View more
  6 in total

1.  CD36 plays a negative role in the regulation of lipophagy in hepatocytes through an AMPK-dependent pathway.

Authors:  Yun Li; Ping Yang; Lei Zhao; Yao Chen; Xiaoyu Zhang; Shu Zeng; Li Wei; Zac Varghese; John F Moorhead; Yaxi Chen; Xiong Z Ruan
Journal:  J Lipid Res       Date:  2019-01-20       Impact factor: 5.922

2.  Arterial Stiffness, Thickness and Association to Suitable Novel Markers of Risk at the Origin of Cardiovascular Disease in Obese Children.

Authors:  Melania Manco; Valerio Nobili; Anna Alisi; Nadia Panera; Aase Handberg
Journal:  Int J Med Sci       Date:  2017-07-12       Impact factor: 3.738

3.  Developmental Exposure to 2,2',4,4'-Tetrabromodiphenyl Ether Induces Long-Lasting Changes in Liver Metabolism in Male Mice.

Authors:  Ahmed Khalil; Mikhail Parker; Richard Mpanga; Sebnem E Cevik; Cassandra Thorburn; Alexander Suvorov
Journal:  J Endocr Soc       Date:  2017-03-14

4.  Plasma sCD36 as non-circadian marker of chronic circadian disturbance in shift workers.

Authors:  Daniella van de Langenberg; Jelle J Vlaanderen; Martijn E T Dolle; Aase Handberg; Roel C H Vermeulen; Linda W M van Kerkhof
Journal:  PLoS One       Date:  2019-10-24       Impact factor: 3.240

5.  MicroRNA-20a-5p Ameliorates Non-alcoholic Fatty Liver Disease via Inhibiting the Expression of CD36.

Authors:  Xin Wang; Yan Ma; Long-Yan Yang; Dong Zhao
Journal:  Front Cell Dev Biol       Date:  2020-12-03

Review 6.  The Multifunctionality of CD36 in Diabetes Mellitus and Its Complications-Update in Pathogenesis, Treatment and Monitoring.

Authors:  Kamila Puchałowicz; Monika Ewa Rać
Journal:  Cells       Date:  2020-08-11       Impact factor: 6.600

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.